

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



**LEPU BIOPHARMA CO., LTD.**  
**樂普生物科技股份有限公司**

*(A joint stock company incorporated in the People's Republic of China with limited liability)*

**(Stock Code: 2157)**

**(1) POLL RESULTS OF THE POSTPONED EGM AND  
POSTPONED CLASS MEETINGS HELD ON SEPTEMBER 23, 2022  
AND**

**(2) AMENDMENTS TO THE ARTICLES OF ASSOCIATION,  
THE RULES OF PROCEDURES FOR THE MEETING OF SHAREHOLDERS,  
THE RULES OF PROCEDURES FOR THE MEETING OF BOARD OF  
DIRECTORS AND THE RULES OF PROCEDURES FOR THE MEETING  
OF SUPERVISORY COMMITTEE**

The Board is pleased to announce that all the resolutions proposed as set out in the Original Notices and the Supplemental Notices were duly passed by the Shareholders by way of poll at the Postponed EGM and Postponed Class Meetings.

References are made to the original notice of the 2022 first extraordinary general meeting (the “**Original Notice of EGM**”), the original notice of the 2022 first class meeting of H Shareholders (the “**Original Notice of Class Meeting of H Shareholders**”), the original notice of the 2022 first class meeting of Domestic Shareholders each dated September 1, 2022 (the “**Original Notice of Class Meeting of Domestic Shareholders**”, and together with the Original Notice of EGM and Original Notice of Class Meeting of H Shareholders, collectively the “**Original Notices**”), the Company’s circular (the “**Circular**”) dated September 1, 2022, the supplemental notice of the postponed 2022 first extraordinary general meeting (the “**Supplemental Notice of EGM**”), the supplemental notice of the postponed 2022 first class meeting of H Shareholders (the “**Supplemental Notice of Class Meeting of H Shareholders**”), the supplemental notice of the postponed 2022 first class meeting of Domestic Shareholders each dated September 8, 2022 (the “**Supplemental Notice of Class Meeting of Domestic Shareholders**”, and together with the Supplemental Notice of EGM and Supplemental Notice of Class Meeting of H Shareholders, collectively the “**Supplemental Notices**”), and the Company’s supplemental circular (the “**Supplemental Circular**”) dated September 8, 2022 of the postponed 2022 first extraordinary general meeting (the “**Postponed EGM**”), the postponed 2022 first class meeting of H Shareholders (the “**Postponed Class Meeting of H Shareholders**”) and the postponed 2022 first class meeting of Domestic Shareholders (the “**Postponed Class Meeting of Domestic Shareholders**”, and together with the Postponed Class Meeting of H Shareholders, collectively the “**Postponed Class Meetings**”).

Capitalised terms used herein shall have the same meanings as those defined in the Circular and the Supplemental Circular unless the context requires otherwise.

## ATTENDANCE AT THE POSTPONED EGM AND THE POSTPONED CLASS MEETINGS

The Postponed EGM and the Postponed Class Meetings were chaired by Dr. Pu Zhongjie, the chairman of the Board and an executive Director. The Postponed EGM was successfully held at Conference Room, Building 7, No. 37 Chaoqian Road, Changping District, Beijing, the PRC on Friday, September 23, 2022 at 5:00 p.m.. The Postponed Class Meeting of H Shareholders and the Postponed Class Meeting of Domestic Shareholders were successfully held immediately after the conclusion of the Postponed EGM and immediately after the conclusion of the Postponed Class Meeting of H Shareholders, respectively on Friday, September 23, 2022. The Postponed EGM and the Postponed Class Meetings were convened in accordance with the requirements of the relevant laws and regulations of the PRC and the Articles of Association, and the poll results of the Postponed EGM and the Postponed Class Meetings were lawful and valid.

The attendance of the Postponed EGM and the Postponed Class Meetings is as follows:

	<b>Class of Shares</b>	<b>Number of Shares in issue (and entitling holders to attend and vote for or against any resolution)</b>	<b>Number of Shares present (in person or by proxy)</b>	<b>Approximate %</b>
Postponed EGM	H Shares	1,605,176,474	1,250,560,475	77.91%
	Domestic Shares	54,268,364	49,295,775	90.84%
	Total	1,659,444,838	1,299,856,250	78.33%
Postponed Class Meeting of H Shareholders	H Shares	1,605,176,474	1,250,560,475	77.91%
Postponed Class Meeting of Domestic Shareholders	Domestic Shares	54,268,364	49,295,775	90.84%

## POLL RESULTS OF THE POSTPONED EGM

The poll results in respect of all the resolutions proposed at the Postponed EGM are as follows:

SPECIAL RESOLUTIONS		NO. OF SHARES VOTED (APPROXIMATE %)		
		FOR	AGAINST	ABSTAIN
1.	To consider and approve the proposed Issue of A Shares as follows (each and every item as a separate resolution):			
	i. Class of new Shares to be issued	1,299,856,250 (100%)	0 (0%)	0 (0%)
	ii. Nominal value of new Shares to be issued	1,299,856,250 (100%)	0 (0%)	0 (0%)
	iii. Issue size	1,299,856,250 (100%)	0 (0%)	0 (0%)
	iv. Target subscribers	1,299,856,250 (100%)	0 (0%)	0 (0%)
	v. Pricing methodology	1,299,856,250 (100%)	0 (0%)	0 (0%)
	vi. Method and schedule of issuance	1,299,856,250 (100%)	0 (0%)	0 (0%)
	vii. Method of underwriting	1,299,856,250 (100%)	0 (0%)	0 (0%)
	viii. Use of Proceeds	1,299,856,250 (100%)	0 (0%)	0 (0%)
	ix. Place of listing	1,299,856,250 (100%)	0 (0%)	0 (0%)
	x. Validity period of the resolutions	1,299,856,250 (100%)	0 (0%)	0 (0%)
2.	To consider and approve the authorization to the Board of Directors and persons authorized by it to fully handle the relevant matters in connection with the Issue of A Shares and the listing on the Sci-Tech Board.	1,299,856,250 (100%)	0 (0%)	0 (0%)
3.	To consider and approve the projects to be funded by the proceeds raised from the Issue of A Shares and feasibility analysis.	1,299,856,250 (100%)	0 (0%)	0 (0%)
4.	To consider and approve the Company's Share price stabilization plan and restraining measures within three years after the initial public offering of A Shares and listing on the Sci-Tech Board.	1,299,856,250 (100%)	0 (0%)	0 (0%)

SPECIAL RESOLUTIONS		NO. OF SHARES VOTED (APPROXIMATE %)		
		FOR	AGAINST	ABSTAIN
5.	To consider and approve the Company's three-year dividend distribution plan for Shareholders after the initial public offering of A Shares and listing on the Sci-Tech Board.	1,299,856,250 (100%)	0 (0%)	0 (0%)
6.	To consider and approve the analysis on dilution on immediate return by the initial public offering of A Shares and recovery measures.	1,299,856,250 (100%)	0 (0%)	0 (0%)
7.	To consider and approve the undertakings and restraining measures relating to the Issue of A Shares and listing on the Sci-Tech Board.	1,299,856,250 (100%)	0 (0%)	0 (0%)
8.	To consider and approve the proposal for the vesting of accumulated profit distribution and the plan for undertaking unrecovered losses prior to the Issue of A Shares.	1,299,856,250 (100%)	0 (0%)	0 (0%)
9.	To consider and approve the use of proceeds raised in previous offering.	1,299,856,250 (100%)	0 (0%)	0 (0%)
10.	To consider and approve the proposed amendments to the Articles in respect of the Issue of A Shares.	1,299,856,250 (100%)	0 (0%)	0 (0%)
11.	To consider and confirm the related party transactions from January 1, 2019 to June 30, 2022.	522,818,997 (100%)	0 (0%)	0 (0%)
ORDINARY RESOLUTIONS		NO. OF SHARES VOTED (APPROXIMATE %)		
		FOR	AGAINST	ABSTAIN
12.	To consider and approve the engagement of intermediaries, including but not limited to Haitong Securities Co., Ltd. (海通證券股份有限公司) as the sponsor/lead underwriter, Zhong Lun Law Firm (北京市中倫律師事務所) as the legal adviser to the Company as to PRC laws, and PricewaterhouseCoopers Zhong Tian LLP (普華永道中天會計師事務所(特殊普通合夥)) as the auditor, for the proposed Issue of A Shares and listing on the Sci-Tech Board, and further authorizes the Board of Directors to determine the remunerations of such intermediaries.	1,299,856,250 (100%)	0 (0%)	0 (0%)
13.	To consider and approve the amendments to the "Rules of Procedures for the Meeting of Shareholders".	1,299,856,250 (100%)	0 (0%)	0 (0%)
14.	To consider and approve the amendments to the "Rules of Procedures for the Meeting of Board of Directors".	1,299,856,250 (100%)	0 (0%)	0 (0%)
15.	To consider and approve the amendments to the "Rules of Procedures for the Meeting of Supervisory Committee".	1,299,856,250 (100%)	0 (0%)	0 (0%)

ORDINARY RESOLUTIONS		NO. OF SHARES VOTED (APPROXIMATE %)		
		FOR	AGAINST	ABSTAIN
16.	To consider and approve the amendments to or adoption of the following internal governance policies:			
	(a) the “Management Policy for Raised Proceeds”	1,299,856,250 (100%)	0 (0%)	0 (0%)
	(b) the “Terms of Reference for the independent non-executive Directors”	1,299,856,250 (100%)	0 (0%)	0 (0%)
	(c) the “Management Policy for Related (Connected) Transactions”	1,299,856,250 (100%)	0 (0%)	0 (0%)
	(d) the “Management Policy for External Guarantees”	1,299,856,250 (100%)	0 (0%)	0 (0%)
17.	To consider and approve the uncovered deficit of the Company amounting to more than one-third of the total Share capital of the Company.	1,299,856,250 (100%)	0 (0%)	0 (0%)

As more than two-thirds of the vote was cast in favour of the special resolutions numbered 1 to 11 above, these resolutions were duly passed as special resolutions.

As more than half of the vote was cast in favour of the ordinary resolutions numbered 12 to 17 above, these resolutions were duly passed as ordinary resolutions.

#### **POLL RESULTS OF THE POSTPONED CLASS MEETING OF H SHAREHOLDERS**

The poll results in respect of all the resolutions proposed at the Postponed Class Meeting of H Shareholders are as follows:

SPECIAL RESOLUTIONS		NO. OF SHARES VOTED (APPROXIMATE %)		
		FOR	AGAINST	ABSTAIN
1.	To consider and approve the proposed Issue of A Shares as follows (each and every item as a separate resolution):			
	i. Class of new Shares to be issued	1,250,560,475 (100%)	0 (0%)	0 (0%)
	ii. Nominal value of new Shares to be issued	1,250,560,475 (100%)	0 (0%)	0 (0%)
	iii. Issue size	1,250,560,475 (100%)	0 (0%)	0 (0%)
	iv. Target subscribers	1,250,560,475 (100%)	0 (0%)	0 (0%)

SPECIAL RESOLUTIONS		NO. OF SHARES VOTED (APPROXIMATE %)		
		FOR	AGAINST	ABSTAIN
v.	Pricing methodology	1,250,560,475 (100%)	0 (0%)	0 (0%)
vi.	Method and schedule of issuance	1,250,560,475 (100%)	0 (0%)	0 (0%)
vii.	Method of underwriting	1,250,560,475 (100%)	0 (0%)	0 (0%)
viii.	Use of Proceeds	1,250,560,475 (100%)	0 (0%)	0 (0%)
ix.	Place of listing	1,250,560,475 (100%)	0 (0%)	0 (0%)
x.	Validity period of the resolutions	1,250,560,475 (100%)	0 (0%)	0 (0%)
2.	To consider and approve the authorization to the Board of Directors and persons authorized by it to fully handle the relevant matters in connection with the Issue of A Shares and the listing on the Sci-Tech Board.	1,250,560,475 (100%)	0 (0%)	0 (0%)
3.	To consider and approve the projects to be funded by the proceeds raised from the Issue of A Shares and feasibility analysis.	1,250,560,475 (100%)	0 (0%)	0 (0%)
4.	To consider and approve the Company's Share price stabilization plan and restraining measures within three years after the initial public offering of A Shares and listing on the Sci-Tech Board.	1,250,560,475 (100%)	0 (0%)	0 (0%)
5.	To consider and approve the Company's three-year dividend distribution plan for Shareholders after the initial public offering of A Shares and listing on the Sci-Tech Board.	1,250,560,475 (100%)	0 (0%)	0 (0%)
6.	To consider and approve the analysis on dilution on immediate return by the initial public offering of A Shares and recovery measures.	1,250,560,475 (100%)	0 (0%)	0 (0%)
7.	To consider and approve the undertakings and restraining measures relating to the Issue of A Shares and listing on the Sci-Tech Board.	1,250,560,475 (100%)	0 (0%)	0 (0%)
8.	To consider and approve the proposal for the vesting of accumulated profit distribution and the plan for undertaking unrecovered losses prior to the Issue of A Shares.	1,250,560,475 (100%)	0 (0%)	0 (0%)

SPECIAL RESOLUTIONS		NO. OF SHARES VOTED (APPROXIMATE %)		
		FOR	AGAINST	ABSTAIN
9.	To consider and approve the use of proceeds raised in previous offering.	1,250,560,475 (100%)	0 (0%)	0 (0%)
10.	To consider and approve the proposed amendments to the Articles in respect of the Issue of A Shares.	1,250,560,475 (100%)	0 (0%)	0 (0%)
11.	To consider and confirm the related party transactions from January 1, 2019 to June 30, 2022.	491,102,926 (100%)	0 (0%)	0 (0%)

As more than two-thirds of the vote was cast in favour of the special resolutions numbered 1 to 11 above, these resolutions were duly passed as special resolutions.

### **POLL RESULTS OF THE POSTPONED CLASS MEETING OF DOMESTIC SHAREHOLDERS**

The poll results in respect of all the resolutions proposed at the Postponed Class Meeting of Domestic Shareholders are as follows:

SPECIAL RESOLUTIONS		NO. OF SHARES VOTED (APPROXIMATE %)		
		FOR	AGAINST	ABSTAIN
1.	To consider and approve the proposed Issue of A Shares as follows (each and every item as a separate resolution):			
	i. Class of new Shares to be issued	49,295,775 (100%)	0 (0%)	0 (0%)
	ii. Nominal value of new Shares to be issued	49,295,775 (100%)	0 (0%)	0 (0%)
	iii. Issue size	49,295,775 (100%)	0 (0%)	0 (0%)
	iv. Target subscribers	49,295,775 (100%)	0 (0%)	0 (0%)
	v. Pricing methodology	49,295,775 (100%)	0 (0%)	0 (0%)
	vi. Method and schedule of issuance	49,295,775 (100%)	0 (0%)	0 (0%)
	vii. Method of underwriting	49,295,775 (100%)	0 (0%)	0 (0%)
	viii. Use of Proceeds	49,295,775 (100%)	0 (0%)	0 (0%)

SPECIAL RESOLUTIONS		NO. OF SHARES VOTED (APPROXIMATE %)		
		FOR	AGAINST	ABSTAIN
	ix. Place of listing	49,295,775 (100%)	0 (0%)	0 (0%)
	x. Validity period of the resolutions	49,295,775 (100%)	0 (0%)	0 (0%)
2.	To consider and approve the authorization to the Board of Directors and persons authorized by it to fully handle the relevant matters in connection with the Issue of A Shares and the listing on the Sci-Tech Board.	49,295,775 (100%)	0 (0%)	0 (0%)
3.	To consider and approve the projects to be funded by the proceeds raised from the Issue of A Shares and feasibility analysis.	49,295,775 (100%)	0 (0%)	0 (0%)
4.	To consider and approve the Company's Share price stabilization plan and restraining measures within three years after the initial public offering of A Shares and listing on the Sci-Tech Board.	49,295,775 (100%)	0 (0%)	0 (0%)
5.	To consider and approve the Company's three-year dividend distribution plan for Shareholders after the initial public offering of A Shares and listing on the Sci-Tech Board.	49,295,775 (100%)	0 (0%)	0 (0%)
6.	To consider and approve the analysis on dilution on immediate return by the initial public offering of A Shares and recovery measures.	49,295,775 (100%)	0 (0%)	0 (0%)
7.	To consider and approve the undertakings and restraining measures relating to the Issue of A Shares and listing on the Sci-Tech Board.	49,295,775 (100%)	0 (0%)	0 (0%)
8.	To consider and approve the proposal for the vesting of accumulated profit distribution and the plan for undertaking unrecovered losses prior to the Issue of A Shares.	49,295,775 (100%)	0 (0%)	0 (0%)
9.	To consider and approve the use of proceeds raised in previous offering.	49,295,775 (100%)	0 (0%)	0 (0%)
10.	To consider and approve the proposed amendments to the Articles in respect of the Issue of A Shares.	49,295,775 (100%)	0 (0%)	0 (0%)
11.	To consider and confirm the related party transactions from January 1, 2019 to June 30, 2022.	49,295,775 (100%)	0 (0%)	0 (0%)

As more than two-thirds of the vote was cast in favour of the special resolutions numbered 1 to 11 above, these resolutions were duly passed as special resolutions.



*Notes:*

1. Save for each of Ningbo Houde Yimin, Lepu Medical, Shanghai Lvyuan and PW Medtech Group Limited, who together hold 759,457,549 Shares and is a Shareholder required to abstain from voting on the resolution numbered (11) on the confirmation of the Company's related party transactions from January 1, 2019 to June 30, 2022 at the Postponed EGM and the Postponed Class Meeting of H Shareholders, there were no Shareholders who were required under the Listing Rules to abstain from voting. There were no Shareholders, who, pursuant to Rule 13.40 of the Listing Rules, were required to abstain from voting in favour of any of the proposed resolutions at the Postponed EGM and the Postponed Class Meeting of H Shareholders.
2. None of the Shareholders have stated their intention in the Circular or the Supplemental Circular to vote against or to abstain from voting on any of the resolutions at the Postponed EGM or Postponed Class Meetings.
3. The Company's H shares registrar, Computershare Hong Kong Investor Services Limited, was appointed as the scrutineer at the Postponed EGM and the Postponed Meeting of H Shareholders for the purpose of vote-taking.
4. All Directors attended the Postponed EGM and the Postponed Class Meetings in person or via electronic means.

**AMENDMENTS TO THE ARTICLES OF ASSOCIATION, THE RULES OF PROCEDURES FOR THE MEETING OF SHAREHOLDERS, THE RULES OF PROCEDURES FOR THE MEETING OF BOARD OF DIRECTORS AND THE RULES OF PROCEDURES FOR THE MEETING OF SUPERVISORY COMMITTEE**

The Board hereby announces that special resolution numbered 10 as set out in the Supplemental Notices in relation to the proposed amendments to the Articles in respect of the Issue of A Shares was duly passed as a special resolution at the Postponed EGM and the Postponed Class Meetings, and ordinary resolutions numbered 13, 14 and 15 as set out in the Supplemental Notice of EGM in relation to the proposed amendments to the Rules of Procedures for the Meeting of Shareholders, the Rules of procedures for the Meeting of Board of Directors and the Rules of Procedures for the Meeting of Supervisory Committee were duly passed as ordinary resolutions at the Postponed EGM. The amendments to the Articles, the Rules of Procedures for the Meeting of Shareholders, the Rules of procedures for the Meeting of Board of Directors and the Rules of Procedures for the Meeting of Supervisory Committee would come into effect after the completion of the issue of A Shares and listing on the Sci-Tech Board. The Company will make consequential change to the number of the relevant articles as a result of the adoption of the amendments to the Articles. Upon the completion of the issue of A Shares and listing on the Sci-Tech Board and the amendments coming into effect, the full text of the amended Articles, the Rules of Procedures for the Meeting of Shareholders, the Rules of procedures for the Meeting of Board of Directors and the Rules of Procedures for the Meeting of Supervisory Committee will be published on the websites of the Stock Exchange and the Company respectively.

On behalf of the Board  
**Lepu Biopharma Co., Ltd.**  
**Dr. Pu Zhongjie**  
*Chairman of the Board and Executive Director*

Shanghai, the PRC, September 23, 2022

*As at the date of this announcement, the board of directors of the Company comprises Dr. Pu Zhongjie (Chairman), Dr. Sui Ziye (Chief Executive Officer) and Dr. Hu Chaohong (Co-Chief Executive Officer) as executive Directors; Ms. Pu Jue, Mr. Yang Hongbing and Mr. Lin Xianghong as non-executive Directors; and Mr. Zhou Demin, Mr. Yang Haifeng and Mr. Fengmao Hua as independent non-executive directors.*